the International Covenant of Economic, Social and Cultural Rights (ICESCR), has resulted in the inclusion of access to essential medicines in the core content of the right to health.
The ICESCR is the text of refer--ence among those international treaties recognizing the right to health. Its article 12 recognizes "the right of everyone to the enjoyment of the highest attainable standard of physical and mental health", mandating "the creation of conditions which would assure to all medical service and medical attention in the event of sickness", among which the Committee has mentioned the supply of essential medicines. The Committee states that the right to health contains a series of interrelated and minimum elements, such as availability, accessibility, accepta a ability and quality of health goods, services and programmes. 2 In this framework, medicines must be available in suffi--cient quantity, without discrimination, overcoming physical and economical constrictions and respecting medical ethics, provided that they are scientifi--cally and medically appropriated. These four elements are in line with the WHO statement that essential medicines are in--tended to be available within the context of health systems in adequate amounts at all times, in the appropriate dosage forms, with assured quality and informa--tion, and at a price that the individual and the community can afford.
Another perspective in the analysis of the relationship between the right to health and access to medicines can be adopted by looking at the obligations to respect, protect and fulfil the right to health undertaken by the states adhering to the ICESCR. The obligation to respect urges states not to violate the right to health with their acts. It imposes, there--fore, obligations of a negative nature, which are translated, in the field of ac--cess to medicines, as not to impede the supply of drugs or introduce arbitrary discriminatory criteria in the supply of them. In pursuance of the obligation to protect, states must prevent infringe--ments of the right committed by third parties -and react against them. The practical applications of this second obligation are those related to medicines' pre-qualification and pharmacovigilance activities. Lastly, the obligation to fulfil .
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Human rights approach to essential medicines Xavier Seuba refers to the adoption of positive mea--sures, be they legislative, budgetary or promotional, needed for the fulfilment of the right to health and, more specifi--cally, access to essential medicines. The Committee has remarked that states adhering to the Covenant take on obligations having immediate effect, such as the prohibition of discrimination and the obligation to ensure that the core content of the rights is complied with. Especially relevant in this regard is the Committee's identification of the supply of essential medicines as part of the core and inviolable content of the said right. Furthermore, states also assume inter--national obligations, as section 2.1 of ICESCR provides that each Member State "undertakes to take steps, individu--ally and through international assistance and cooperation" with a view to achiev--ing the realization of the rights recog--nized in the Covenant. When dealing with the relationship between this aspect and the right to health, the Committee has pronounced that states must ensure that the right to health is given due at--tention in international agreements.
As far as the relationship between the protection of intellectual property and access to essential drugs is con--cerned, it is often said that medicines included in the WHO Model List are not protected by patent but, even if they were, various international trea--ties would also protect property rights. The first statement is clearly wrong, as there are patented medicines in the list. Moreover, an increase in the number of patented medicines included in the list is foreseen resulting from the gradual adoption of selection criteria based on need and not on cost, to which can be added a renewed objectivity commit--ment in the selection process by WHO. 3 With regard to whether property rights should prevail over the right to health, the United Nations Sub-Commission on the Promotion and Protection of Human Rights has pointed out that the right to the protection of moral and economic interests resulting from scientific re--search is a human right "subject to pub--lic interest limitations". 4 In this sense, within the framework of the World Trade Organization (WTO) Dispute Settlement Understanding, the right to access to essential medicines provides powerful arguments to states reported to be infringing intellectual property rights. In such a case, states could argue that by taking action to guarantee a minimum access to essential medicines, they are just complying with another international obligation.
Approaching access to essential medicines as a right not only opens a subjective dimension that refers to individual enforceability of the right to health, but modifies issues such as the relationship between access to medicines and intellectual property rights, strength--ening the patient's position. Likewise, it allows a merely ethical valorization to be overcome in favour of the analysis of ac--tions adopted in the framework of public health in a context of legal enforceability. Finally, the perspective emerging from the right of access to essential medicines provides simultaneously the tools to re--port violations and a useful framework to guide states' pharmaceutical policies in a positive direction. O Competing interests: none declared.
Résumé
Liste modèle OMS des médicaments essentiels : une approche fondée sur les droits de l'homme Depuis l'adoption de la première liste modèle OMS des médicaments essentiels en 1977, celle-ci est devenue un outil très populaire parmi les professionnels de santé et les Etats Membres. Les efforts conjoints de l'OMS et du Comité des Droits économiques, sociaux et culturels de l'ONU ont abouti à ce que l'accès aux médicaments essentiels fasse partie intégrante du droit à la santé. Le Comité stipule que le droit à la santé recouvre une série d'éléments comme la disponibilité, l'accessibilité, l'acceptabilité et la qualité des biens, services et programmes de santé. Ces éléments sont conformes à la position de l'OMS selon laquelle des médicaments essentiels de qualité vérifiée doivent être disponibles à tout moment dans le cadre des systèmes de santé, en quantités suffisantes, sous des formes pharmaceutiques appropriées, avec une qualité garantie et accompagnés des informations nécessaires et à un prix abordable pour l'individu et pour la communauté. L'auteur aborde un autre point de vue en examinant l'obligation de respecter, de protéger et de faire appliquer le droit à la santé à laquelle ont souscrit des Etats Membres en adhérant au Pacte international relatif aux droits économiques, sociaux et culturels et étudie les relations entre l'accès aux médicaments, la protection de la propriété intellectuelle et les droits de l'homme.
Desde su adopción en 1977, la Lista Modelo OMS de Medicamentos Esenciales se ha convertido en un instrumento popular entre los profesionales de la salud y los Estados Miembros. El esfuerzo conjunto realizado por la OMS y el Comité de Derechos Económicos, Sociales y Culturales de las Naciones Unidas ha desembocado en la inclusión del acceso a los medicamentos esenciales entre los componentes centrales del derecho a la salud. El Comité señala que el derecho a la salud abarca una serie de elementos, como la disponibilidad, accesibilidad, aceptabilidad y calidad de los productos, servicios y programas de salud, que están en consonancia con la declaración de la OMS de que los
Resumen
Derechos humanos y Lista Modelo OMS de Medicamentos Esenciales
medicamentos esenciales deben estar disponibles en todo momento en las cantidades adecuadas y en las formas farmacéuticas que se requieran en el ámbito de los sistemas de salud, con la calidad e información necesarias, y a un precio asequible para los individuos y la comunidad. Desde otra perspectiva, el autor considera las obligaciones de respetar, proteger y cumplir el derecho a la salud asumidas por los Estados que se han adherido al Pacto Internacional de Derechos Económicos, Sociales y Culturales (ICESCR), y analiza la relación entre el acceso a los medicamentos, la protección de la propiedad intelectual y los derechos humanos. 
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Round Table Discussion
Drug development incentives to improve access to essential medicines
James Packard Love a
It is hardly a matter of controversy that, as a general principle, access to essential medicines is an issue of human rights. The Universal Declaration on Human Rights makes reference to the right to medical care (Article 25) and the right to share in the benefits of scientific advancements (Article 27). Countless declarations -such as those relating to access to treatment for acquired immunodeficiency syndrome (AIDS), the WHO re--vised drug strategy and the WTO Doha Declaration on TRIPS and Public Health -have focused on the need for govern--ments to promote access to medicines for all. The interesting question is not whether access to medicine is a human right but, rather, how governments intend to give practical effect to these lofty aspirations.
We live in a world of vast disparities of incomes and opportunities, which translate into vast disparities of access to decent housing, medical services, education and many other elements relevant to human rights. Often, too, there are vast disparities in terms of access to medicines, but this need not be inevitable.
Medicines are knowledge goods, sharing an important characteristic with many other knowledge goods. It may be expensive to develop a medicine, but it is often not expensive to copy one. An AIDS drug such as stavudine that sells for US$ 3800 for a year of treatment in the United States is copied as a generic product for about US$ 21 for a year of treatment.
While it is nearly impossible to avoid having to make tough choices for scarce physical goods and services, knowledge goods are different. Scarcity is a deliberate choice, enforced through social mechanisms such as patents, which create monopolies and predictably drive prices far above the costs of making copies. Do we need to make knowledge goods expensive, and then deal with the inevitable disparities of ac--cess associated with high prices? Or can we imagine different incentives for drug development that would coexist with pric--ing at marginal cost?
In 2005, Representative Sanders introduced HR 417 in the US Congress. This legislation is a working model for a new paradigm for drug development -the Medical In--novation Prize Fund -that would provide huge rewards for the development of new drugs without introducing artificial scarcity for new inventions. It would go much further towards choosing abundance over scarcity, by creating a rational, evidence-based system for rewarding inventions to provide better health outcomes. It also provides incentives to develop products that would address global public health problems, including new treatments for neglected diseases such as malaria or emerging health problems such as severe acute respiratory syndrome (SARS) or avian flu.
The Medical Innovation Prize Fund would eliminate market monopolies for medicines in the United States, driving prices close to marginal costs. It is not an attack on intellectual property but a new system of intellectual property: one that separates the market for innovation from the market for the physical copies of the knowledge good.
The Prize Fund approach would require a new global trade framework to deal with the issue of sharing the global burden of the costs of research and development. In a separate but related effort, a new global trade framework has been proposed that would obligate governments to support R&D, but would give them much flexibility in the mechanisms they adopt to do so. It would also create a system for identifying and stimulating R&D in the areas of the greatest need and priority, including new medicines for poor populations. 1, 2 Taken together, the Medical Innovation Prize Fund and the medical R&D treaty 2 trace a serious and important road map towards fulfilling the lofty aspirations of human rights to essential medicines, in a manner that is consistent with sustain--able financial support for R&D on new medicines. O Competing interests: none declared. 
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Round Table Discussion Rights and practical access to medicines Jonathan Kahn a The argument that access to essential medicines should be con--sidered as a fundamental element when assessing compliance with the right to health is reasonable and well considered. As public health and biomedical interventions have increasingly come to rely on medicines as a central component to securing good health, it makes sense to incorporate such interventions into our concepts of basic rights. A couple of caveats should nevertheless be considered. First, in emphasizing the value of medicines it is important to avoid an overreliance or overemphasis on pharmaceuticals as the answer to the world's major health problems. Broader social, political and economic programmes concerning the equitable and efficient management of an array of public goods should not be eclipsed by an excessive reliance on medicines as a means of bringing health to populations. Certainly, the considerations raised by such issues as access to medicines to treat AIDS demand attention, but when addressing broader health issues it is important to keep in mind that dealing with individual maladies at the molecular level should not distract us from focusing on social conditions that may be largely re--sponsible for causing the maladies in the first place.
Second, as regards the intellectual property issues involved in guaranteeing access to essential medicines, protection of intellectual property rights is indeed generally "subject to public interest limitations". Such limitations, however, are often difficult to define and even more difficult to invoke. It is worth noting that, in the United States at least, many of the patents underlying medicines are based on research that was conducted with state funding. The fruits of such research have been patentable only since 1984 when the US Government passed the Bayh-Dole Act. I would argue that modifying this Act to recognize a right of access to essential medicines could be a constructive model for incorporating this element into the right to health. Specifically, the Act could be amended to stipulate that, if products were developed with federal fund--ing, the federal government would retain the power to issue a compulsory licence on behalf of the patent holder to relevant generic manufacturers to produce the drug on reasonable terms in such a manner as to make it available and accessible in places where it would not otherwise be so. Alternatively, the amendment might delegate power to WHO or an equivalent organization to issue the compulsory licence.
This approach would provide notice to patent holders that their products might be subject to a rights-based compul--sory licence. It also would allow for health activists to focus their attentions on lobbying a democratically responsive political institution rather than trying to bargain with individual private pharmaceutical corporations whose primary responsibility is to their shareholders. O
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